Pediatr Infect Dis J

• 

  Publication Venue For

  • Racial Inequities in Sepsis Mortality Among Children in the United States..  42:361-367. 2023
  • Exposure-response Relationships of Metronidazole in Infants: Integration of Electronic Health Record Data With Population Pharmacokinetic Modeling-derived Exposure Simulation..  42:27-31. 2023
  • Breast Milk and Saliva for Postnatal Cyto†megalovirus Screening among Very Low Birth Weight Infants..  41:904-910. 2022
  • Solithromycin in Children and Adolescents With Community-acquired Bacterial Pneumonia..  41:556-562. 2022
  • Severe Congenital Syphilis in the Neonatal Intensive Care Unit: A Retrospective Case Series..  41:335-339. 2022
  • Pharmacokinetics and Safety of Ceftobiprole in Pediatric Patients..  40:997-1003. 2021
  • Antibiotic Safety and Effectiveness in Premature Infants With Complicated Intraabdominal Infections..  40:550-555. 2021
  • Long-term Outcomes after Postnatal Cytomegalovirus Infection in Low Birthweight Preterm Infants: A Systematic Review..  40:571-581. 2021
  • Epidemiology, Clinical and Microbiologic Profile and Risk Factors for Inpatient Mortality in Pediatric Severe Sepsis in the United States From 2003 to 2014: A Large Population Analysis..  39:781-788. 2020
  • Safety of Metronidazole in Late Pre-term and Term Infants with Complicated Intra-abdominal Infections..  39:e245-e248. 2020
  • Dosing of Antimicrobials in the Neonatal Intensive Care Unit: Does Clinical Practice Reflect Pharmacokinetics-based Recommendations?.  39:713-717. 2020
  • Hospital-acquired Pneumonia and Ventilator-associated Pneumonia in Children: A Prospective Natural History and Case-Control Study..  39:658-664. 2020
  • Paradoxical Antibiotic Effect of Ampicillin: Use of a Population Pharmacokinetic Model to Evaluate a Clinical Correlate of the Eagle Effect in Infants With Bacteremia..  39:725-729. 2020
  • A Pharmacoepidemiologic Study of the Safety and Effectiveness of Clindamycin in Infants..  39:204-210. 2020
  • HIV-1 Drug Resistance and Virologic Outcomes Among Tanzanian Youth Living With HIV..  38:617-619. 2019
  • Positive 2-Tiered Lyme Disease Serology is Uncommon in Asymptomatic Children Living in Endemic Areas of the United States..  38:e105-e107. 2019
  • Predictors of Poor Outcomes Among Infants With Respiratory Syncytial Virus-associated Acute Lower Respiratory Infection in Botswana..  38:525-527. 2019
  • Safety, Effectiveness and Exposure-response of Micafungin in Infants: Application of an Established Pharmacokinetics Model to Electronic Health Records..  38:e26-e28. 2019
  • Pneumococcal Colonization and the Nasopharyngeal Microbiota of Children in Botswana..  37:1176-1183. 2018
  • A Phase 3 Study of Micafungin Versus Amphotericin B Deoxycholate in Infants With Invasive Candidiasis..  37:992-998. 2018
  • Voriconazole Treatment for an Infant With Intractable Candida glabrata Meningitis..  37:999-1001. 2018
  • Antifungal Susceptibility and Clinical Outcome in Neonatal Candidiasis..  37:923-929. 2018
  • Macro- and Microvascular Parameters After Toxic Shock Syndrome..  37:e228-e230. 2018
  • Exposure-Response Analysis of Micafungin in Neonatal Candidiasis: Pooled Analysis of Two Clinical Trials..  37:580-585. 2018
  • The Nasopharyngeal Microbiota of Children With Respiratory Infections in Botswana..  36:e211-e218. 2017
  • Use of Population Pharmacokinetics and Electronic Health Records to Assess Piperacillin-Tazobactam Safety in Infants..  36:855-859. 2017
  • Late-onset Sepsis in Extremely Premature Infants: 2000-2011..  36:774-779. 2017
  • Dalbavancin Pharmacokinetics and Safety in Children 3 Months to 11 Years of Age..  36:645-653. 2017
  • Early Antiretroviral Therapy Initiation and Mortality Among Infants Diagnosed With HIV in the First 12 Weeks of Life: Experiences From Kinshasa, DR Congo and Blantyre, Malawi..  36:654-658. 2017
  • Performance of HIV Rapid Tests Among Breastfeeding, Malawian Infants..  36:405-411. 2017
  • Safety of High-dose Acyclovir in Infants With Suspected and Confirmed Neonatal Herpes Simplex Virus Infections..  36:369-373. 2017
  • Safety and Immunogenicity of DTaP5-IPV Compared With DTaP5 Plus IPV as the Fifth Dose in Children 4-6 Years of Age..  36:319-325. 2017
  • Pharmacokinetics and Safety of Micafungin in Infants Supported With Extracorporeal Membrane Oxygenation..  35:1204-1210. 2016
  • Providing Safe and Effective Preventative Antiretroviral Prophylaxis to HIV-exposed Newborns via a Novel Drug Delivery System in Tanzania..  35:987-991. 2016
  • Chest Radiographic Findings and Outcomes of Pneumonia Among Children in Botswana..  35:257-262. 2016
  • Survival Benefit of Empirical Therapy for Staphylococcus aureus Bloodstream Infections in Infants..  34:1175-1179. 2015
  • The Positive Predictive Value of Lyme Elisa for the Diagnosis of Lyme Disease in Children..  34:1260-1262. 2015
  • Cefepime and Ceftazidime Safety in Hospitalized Infants..  34:964-968. 2015
  • Neonatal Escherichia coli Bloodstream Infections: Clinical Outcomes and Impact of Initial Antibiotic Therapy..  34:933-936. 2015
  • Cryptococcal osteomyelitis in an adolescent survivor of T-cell acute lymphoblastic leukemia..  34:662-666. 2015
  • No survival benefit with empirical vancomycin therapy for coagulase-negative staphylococcal bloodstream infections in infants..  34:371-375. 2015
  • Pain in adolescent girls receiving human papillomavirus vaccine with concomitantly administered vaccines..  34:200-202. 2015
  • Vancomycin cerebrospinal fluid pharmacokinetics in children with cerebral ventricular shunt infections..  33:e270-e272. 2014
  • Late-onset bloodstream infections in hospitalized term infants..  33:920-923. 2014
  • Clinical and immune responses to inactivated influenza A(H1N1)pdm09 vaccine in children..  33:865-871. 2014
  • Changes in childhood pneumonia and infant mortality rates following introduction of the 13-valent pneumococcal conjugate vaccine in Nicaragua..  33:637-642. 2014
  • Tuberculosis Immune Reconstitution Inflammatory Syndrome in children initiating Antiretroviral Therapy for HIV infection: A systematic literature review..  33:499-503. 2014
  • Predictors of positive cerebrospinal fluid cultures in infants with bacteremia..  33:360-365. 2014
  • Population pharmacokinetics of intravenous acyclovir in preterm and term infants..  33:42-49. 2014
  • Immunogenicity of Haemophilus influenzae type b protein conjugate vaccines in very low birth weight infants..  32:1400-1402. 2013
  • Population Pharmacokinetics of Intravenous Acyclovir in Preterm and Term Infants. 2013
  • Determining population and developmental pharmacokinetics of metronidazole using plasma and dried blood spot samples from premature infants..  32:956-961. 2013
  • Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants..  32:748-753. 2013
  • Prevalence of mycobacteremia among HIV-infected infants and children in northern Tanzania..  32:754-756. 2013
  • Group B Streptococcus and Escherichia coli infections in the intensive care nursery in the era of intrapartum antibiotic prophylaxis..  32:208-212. 2013
  • Risk factors for invasive candidiasis in infants >1500 g birth weight..  32:222-226. 2013
  • Detecting respiratory viruses in asymptomatic children..  31:1221-1226. 2012
  • Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates..  31:1252-1257. 2012
  • Pharmacokinetics and safety of fluconazole in young infants supported with extracorporeal membrane oxygenation..  31:1042-1047. 2012
  • Pharmacokinetics and tolerability of single-dose daptomycin in young infants..  31:935-937. 2012
  • Use of the complete blood cell count in early-onset neonatal sepsis..  31:799-802. 2012
  • Use of the complete blood cell count in late-onset neonatal sepsis..  31:803-807. 2012
  • Commentary: pediatric antifungal drug development: lessons learned and recommendations for the future..  31:635-637. 2012
  • Therapeutic monitoring of voriconazole in children less than three years of age: a case report and summary of voriconazole concentrations for ten children..  31:632-635. 2012
  • Antifungal therapy and outcomes in infants with invasive Candida infections..  31:439-443. 2012
  • Pharmacokinetics of moxifloxacin in an infant with Mycoplasma hominis meningitis..  31:197-199. 2012
  • Cryptococcus gattii genotype VGI infection in New England..  30:1111-1114. 2011
  • Population pharmacokinetics of meropenem in plasma and cerebrospinal fluid of infants with suspected or complicated intra-abdominal infections..  30:844-849. 2011
  • A statement regarding personal belief exemption from immunization mandates: from the Pediatric Infectious Diseases Society, March 2011..  30:606-607. 2011
  • Fluconazole loading dose pharmacokinetics and safety in infants..  30:375-378. 2011
  • Heptavalent pneumococcal conjugate vaccine immunogenicity in very-low-birth-weight, premature infants..  29:600-606. 2010
  • Burden of childhood rotavirus disease on health systems in the United States..  29:e19-e25. 2010
  • Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study..  29:105-110. 2010
  • Kingella kingae endocarditis and a cluster investigation among daycare attendees..  29:86-88. 2010
  • Early and late onset sepsis in late preterm infants..  28:1052-1056. 2009
  • Trivalent inactivated influenza virus vaccine given to two-month-old children: an off-season pilot study..  28:1099-1104. 2009